Letrozole is of particular interest to bodybuilders and athletes. It has been proven to reduce estrogen levels by 98% or more. This is obviously of enormous interest to bodybuilders.
Femaralyn – Letrozole 2.5mg – 50tabs – Driada Medical
New31.00€
Description
Driada Medical’s Letrozole is a drug developed to fight breast cancer by inhibiting aromatization. It is generally used as an aggressive treatment in post-menopausal women, to combat and reverse the spread of breast cancer after other treatments have failed (such as tamoxifen therapy). Probably the most effective product on the market for this purpose today, it is very similar in structure and action to its predecessor arimidex.
Letrozole is also of particular interest to bodybuilders and athletes. Firstly, it has been proven to reduce estrogen levels by 98% or more. This is obviously of enormous interest to bodybuilders. Indeed, less estrogen in the body eliminates steroid side effects such as water retention, gynecomastia and acne. This makes Letrozole one of the best anti-estrogens on the market, even for very difficult cycles. Also, if you’re competing in bodybuilding competitions, Letrozole helps build lean, striated muscle. The effective dose for Letrozole is 2.5 to 5mg per day. If you exceed this dose, there may be a risk of loss of libido. What’s more, if you keep your estrogen levels too low for too long, you’ll end up weakening your immune system.
Dosage: Take 1 or 2 of 2.5 mg tablets daily during or after cycle.
You must be logged in to post a review.
Shipping information for Warehouse Driada
- Shipping cost: 28$
- FREE SHIPPING FROM 200$ WITH COUPON-CODE DRI
- Shipping: 2 – 3 days (excluding weekends) after validation of your payment.
- Duration of transit: 4-7 days for Europe.
- Sending the tracking code: 2 days after shipping the package.
Available countries:
Shipping only to Europe (Spain, France, Italy, Belgium, Portugal …). NO Shipping to Switzerland, Sweden, Denmark, Finland, or other countries other than EUROPE.
Reviews
There are no reviews yet.